EFFECTS OF METOPROLOL ON HAEMODYNAMIC RESPONSE TO CARBON DIOXIDE PNEUMOPERITONEUM FOR LAPAROSCOPIC SURGERY

Dhurjoti Prosad Bhattacharjee1, Sujata Ghosh2, Souvik Saha3, Debdas Saha4, Gautam Piplai5, Parveen Banu6, Kabita Dubey7, Shibshankar Roy Chowdhury8

ABSTRACT: BACKGROUND: Carbon dioxide pneumoperitoneum for laparoscopic surgery increases arterial pressures, heart rate and systemic vascular resistance. In this randomized double-blind placebo-controlled clinical study, we investigated the efficacy of metoprolol to provide perioperative haemodynamic stability in patients undergoing laparoscopic cholecystectomy. METHODS: Fifty patients, of either sex (20-40 yrs of age) undergoing elective laparoscopic cholecystectomy were randomly allocated in two groups containing 25 patients each. Group M received bolus dose of 10mg intravenous metoprolol before pneumoperitoneum. Group S received 0.9% saline of same volume. RESULTS: Mean arterial pressure and heart rate in Group M were significantly less throughout the period of pneumoperitonium. Intravenous labetalol was required in 52% (13 out of 25) patients in group S to control intraoperative hypertension and it was clinically significant in comparison to group M. CONCLUSION: Metoprolol attenuates the adverse haemodynamic response to pneumoperitoneum and provide haemodynamic stability during laparoscopic surgery. KEYWORDS: Metoprolol, pneumoperitoneum, haemodynamics, laparoscopic surgery.

INTRODUCTION: Carbon dioxide is commonly used to create pneumoperitoneum for laparoscopic surgical procedures.1,2 Both carbon dioxide and pneumoperitoneum cause adverse cardiovascular effects.3 Adverse cardiovascular changes are characterized by elevation of arterial pressure and systemic vascular resistance and decreased cardiac output.4 These haemodynamic responses are mainly due to increased release of catecholamines, vasopressin or both.5,6 Attenuation of adverse haemodynamic response to pneumoperitoneum is usually done by opioids,7 vasodilators8 and alpha2 adrenergic agonists.9,10 Metoprolol, a cardioselective beta1 adrenoceptor antagonist, has been used to control tachycardia and hypertension. Esmolol, an ultrashort-acting cardioselective beta1 adrenoceptor antagonist, also blunts adrenergic responses to perioperative noxious stimuli effectively.11 Vucevic M and colleagues12 have shown that esmolol is effective in attenuating the adverse haemodynamic response to laryngoscopy and endotracheal intubation.12 Therefore due to the similar pharmacodynamics of metoprolol (Being a cardio-selective beta1 adrenoceptor antagonist like esmolol), the researchers hypothesized that a bolus dose of metoprolol administered before pneumoperitoneum would be able to attenuate the adverse haemodynamic response to laparoscopic surgery.

METHODS: The study protocol was approved by the Institutional Ethics Committee and informed consent was obtained from the individual patients. Fifty American Society of Anesthesiologists’ (ASA) grade I and II patients, aged 20-40 years, undergoing elective laparoscopic cholecystectomy under
general anesthesia were randomly assigned to one of the two groups of 25 patients each: Group M (Metoprolol group) and Group S (Control group). Before performing the study it was hypothesized, based on the review of the published literature and our clinical experience, that the hemodynamic effects pneumoperitoneum (Hypertension, tachycardia) will be evident in at least 70% of the patients. Considering an absolute improvement in the primary outcome by 40% in the study group by the addition of metoprolol (i.e. not more than 30% patients will have hypertension and tachycardia following pneumoperitoneum) can be considered as clinically relevant and based on a type I error level of 0.05; type II error level of 0.2, and a two sided test, we needed 21 patients in each treatment groups. Therefore to accommodate the probable drop outs a number of 25 patients in each group were included.

Patients with pre-existing hypertension, bronchial asthma, diabetes, sinus bradycardia and severe hepatic, renal, endocrine and cardiac dysfunction were excluded from the study. Patients were then randomly allocated (Using computer derived random number sequence) into two groups (n=25) to receive one of the following regimens: metoprolol 10mg in 10ml (Group M) or saline 0.9% 10ml (Group S). Identical syringes containing the study drug or saline were prepared and kept in sealed envelopes by another investigator blinded to the randomization. The anesthesiologist who administered anesthesia to the patient was unaware of the nature of study drug administered.

All the patients were given diazepam 10mg and ranitidine 150mg orally on the night before surgery and tab. Ranitidine was repeated on the day of surgery, two hours before induction, with sips of water. On arrival to operation theatre, routine ASA monitoring (Electrocardiography, pulse oxymetry, noninvasive blood pressure) was started and baseline vital parameters e.g. heart rate (HR), mean arterial blood pressure (MAP) and arterial oxygen saturation (SpO₂) were recorded. An intravenous line was started. Patients were induced with fentanyl 2µg/kg and propofol 2mg/kg intravenously (IV). Endotracheal intubation was facilitated by muscle relaxant rocuronium 0.7 mg/kg. Anesthesia was maintained with 33% O₂ in N₂O, 0.6% isoflurane and intermittent bolus dose of rocuronium. Patients received top-up of IV fentanyl 1µg/kg at half hourly intervals. Group M patients received metoprolol 10mg intravenously as a bolus dose before pneumoperitoneum and those allocated in Group S received same volume of 0.9% saline. CO₂ was insufflated into the peritoneal cavity to create pneumoperitoneum. Intra-abdominal pressure (IAP) was maintained up to 12mm Hg throughout the laparoscopic procedure. All the patients were positioned in a head-up tilt of 15°. The patients were mechanically ventilated to keep end-tidal carbon dioxide (EtCO₂) between 35-45 mmHg. Inj. Paracetamol 1000 mg was infused IV in every patient.

In cases of acute and severe haemodynamic fluctuations, the following medical interventions were taken: i) bradycardia (Heart rate <60 beats/min), bolus dose of 0.6mg atropine IV; ii) hypotension (MAP<60mm Hg), increased rate of infusion of IV fluid and/or bolus dose of phenylephrine 100mcg IV and; iii) hypertension (MAP>110mm Hg) bolus dose of labetalol 5mg IV.

At the end of the surgery, ondansetron 4mg was administered IV for prophylaxis against nausea and vomiting. Residual neuromuscular block was reversed with appropriate doses of neostigmine and glycopyrrolate and tracheal extubation was performed. HR and MAP were recorded at the following points of time:

1. Prior to induction.
2. 3 minutes after endotracheal intubation.
3. Before pneumoperitoneum.
4. 15 minutes after pneumoperitoneum.
Patients were observed for adverse events e.g. bradycardia, hypotension, hypertension during postoperative period in post-anesthesia care unit.

**STATISTICAL ANALYSIS:** The numerical data obtained from the study were expressed as Mean±SD. Student’s t test was employed to calculate the statistical differences in continuous variables between the groups, categorical variables were compared with Chi-square test (or Fisher’s exact test; as applicable). A ‘p’ value of <0.05 was considered to be statistically significant. SSPS; version 16.0 (SPSS, Chicago, IL) was used for analysis.

**RESULTS:** The patients allocated in the Group M and Group S were comparable with respect to age, distribution of gender, body weight and the duration of surgery (Table 1). No significant difference was found between the preoperative MAP and the MAP values following intubation (p>0.05, Table 2). Prior to the induction of anesthesia, following the endotracheal intubation and before the initiation of pneumoperitoneum, the MAP and HR values were comparable between the groups (p>0.05). However following pneumoperitoneum both the MAP and HR values in Group M were significantly lower compared to Group S, at 15 min, 30 min, following the release of CO₂ and after extubation (p<0.05, Tables 3, 4).

No patient of either of the Groups suffered from hypotension and bradycardia in our study. Hypertension occurred in 13 patients (52%) of group S whereas no patient of group M suffered from hypertension.

**DISCUSSION:** In the study, we observed the effects of metoprolol, administered before pneumoperitoneum, on haemodynamics in patients undergoing laparoscopic cholecystectomy.

In laparoscopic surgery, CO₂ is routinely used to create pneumoperitoneum.¹,² Immediately after pneumoperitoneum, plasma levels of catecholamines and vasopressin are increased. Increased catecholamine level activates the renin-angiotensin–aldosterone–system (RAAS) leading to some of the characteristic haemodynamic alterations like elevated arterial pressure and increased systemic/pulmonary vascular resistance.⁴,⁵ Vasopressin also contributes to elevation of arterial pressure by increasing the systemic vascular resistance.⁶ Drugs like clonidine,⁹ dexmedetomidine¹⁰ and magnesium sulphate¹³ have been successfully used for attenuating the rise in MAP and HR in response to pneumoperitoneum during laparoscopic surgery.

Metoprolol, a short acting cardioselective beta-adrenoceptor antagonist, has been used to control tachycardia and hypertension in the perioperative period. It is the prototype of cardioselective (β₁) blockers. Onset of action of IV metoprolol is immediate. Half-life varies from 2.8 to 7.5 hours. Since catecholamines released during pneumoperitoneum have positive chronotropic and inotropic actions, β₁ receptor antagonist like metoprolol slows the heart rate and decreases myocardial contractility. When tonic stimulation of β receptors is low, this effect is correspondingly modest. However, when sympathetic nervous system is activated as during pneumoperitoneum during laparoscopic surgery, metoprolol may attenuate the expected rise in heart rate and arterial pressure.
Esmolol is an ultrashort-acting cardioselective $\beta_1$ adrenoceptor antagonist and is found effective to attenuate adrenergic responses to perioperative noxious stimuli.$^{11,12,14}$ Koivusalo A.M. and colleagues$^{15}$ have used esmolol in an initial bolus of 1mg/kg before pneumoperitoneum and followed by an infusion of 200mcg/kg/min. They observed that esmolol was effective in attenuating the rise of heart rate and arterial pressure during laparoscopic surgery.$^{15}$ Based on the results of studies using esmolol, we planned to conduct our study using metoprolol as both the drugs are cardioselective $\beta_1$ blocker and metoprolol is much cost effective than esmolol.

There are very few studies on the efficacy metoprolol to attenuate adverse haemodynamic response during perioperative period. Magnusson$^{16}$ and colleagues conducted a study to find out the efficacy of metoprolol to attenuate the stress response to microaryngoscopy. They administered 200 mg metoprolol orally as slow release tablet for 4days before surgery including the morning of the surgery and 10mg IV as bolus dose before induction. They observed that metoprolol decreased heart rate and general level of arterial pressure during anesthesia but did not affect the fluctuations in arterial pressure.$^{16}$ Based on the IV bolus dose of metoprolol used in the above study, we have selected the IV bolus dose of 10mg metoprolol and observed its efficacy to attenuate the adverse haemodynamic response to pneumoperitonum.

Baseline MAP and MAP after intubation and before pneumoperitoneum was comparable between the two groups. But MAP was significantly lower throughout the period of CO$_2$ pneumoperitonum and after extubation in patients of group M compared to patients of group S. We observed the similar finding in case of heart rate too. So bolus dose of metoprolol administered intravenously before pneumoperitoneum was effective in attenuating the increase in mean arterial pressure (MAP) and heart rate (HR) during CO$_2$ pneumoperitoneum.

Diamant et al$^{17}$ reported 35% decrease in cardiac output in dogs with a raised IAP of 40mmHg. Ishizaki et al$^{18}$ tried to evaluate the safe IAP during laparoscopic surgery. They observed significant fall in cardiac output at 16 mm Hg of IAP and haemodynamic alterations were much less at 12mmHg of IAP. So in our study, we kept IAP 12mm Hg. In spite of maintaining normocapnia and keeping IAP 12mmHg, there was significant rise of MAP and HR in patients of Group S during pneumoperitoneum. However in Group M, haemodynamic responses to pneumoperitonum were effectively blunted and both the MAP and HR were remained at a significantly lower level compared to Group S.

As far as the adverse effects are concerned, no patient of either group suffered from hypotension and bradycardia in our study. Hypertension occurred in 13 patients (52%) of Group S for which they had to be treated with inj. labetalol whereas no patient of Group M suffered from hypertension.

**CONCLUSION:** Metoprolol attenuates the elevation of mean arterial pressure and heart rate during and after pneumoperitoneum and thereby provides haemodynamic stability during laparoscopic surgery.
REFERENCES:
1. Hodgeson G, MC Clelland RMA, Newton JR. Some effects of the peritoneal insufflation of carbon-dioxide. Anaesthesia 1970; 25: 382-389.
2. Blobner M, Felber AR, Gogler S. Carbon-dioxide uptake from the pneumoperitoneum during laparoscopic cholecystectomy. Anesthesiology 1992; 77: A 37-40.
3. Richardson JD, Trinkli EK. Haemodynamic and respiratory alterations with increased intra-abdominal pressure. J. Surg Res 1976; 20: 401-03.
4. Lenz RJ, Thomas TA, Wilkins DG. Cardiovascular changes during laparoscopy: Studies of stroke volume and cardiac output using impedance cardiography. Anaesthesia 1976; 31: 4-7.
5. Myre K, Rostrup M, Buanes T, Stokland O. Plasma catecholamines and haemodynamic changes during pneumoperitoneum. Acta Anaesthesiol Scand 1998; 42: 343-7.
6. Walder AD, Aitkenhed AR. Role of vasopressin in the haemodynamic response to laparoscopic cholecystectomy. Br J Anaesth 1997; 78: 264-6.
7. Lentscherer C, Axler O, Fernandez H. Haemodynamic changes and vasopressin release are not consistently associated with carbon dioxide pneumoperitoneum in humans. Acta Anaesthesiol Scand 2001; 45: 527-35.
8. Joris JL, Hamoir EE, Hartstein GM. Haemodynamic changes and catecholamine release during laparoscopic adrenalectomy for pheochromocytoma. Ansth analg 1999; 88: 16-21.
9. Joris JL, Chiche JD, Canivet JL, Jacquet NJ, Legros JJ, Lamy ML. Haemodynamic changes induced by laparoscopy and their endocrine correlates: effects of clonidine. J Am Coll Cardiol 1998; 32: 1389-96.
10. Bhattacharjee DP, Nayak SK, Dawn S, Bandyopadhyay G, Gupta K. Effects of dexmedetomidine on haemodynamics in patients undergoing laparoscopic cholecystectomy-a comparative study. J Anaesth Pharmacol 2010; 26(1): 45-8.
11. Fuhrman T, Ewell C, Pippin W, Weawer J. Comparison of the efficacy of esmolol and alfentanil to attenuate the haemodynamic response to emergence and extubation. J Clin Anesth 1992; 4: 444-7.
12. Vucevic M, Purdy G, Ellis F. Esmolol hydrochloride for management of the cardiovascular stress responses to laryngoscopy and tracheal intubation. Br J Anaesth 1992; 68: 529-30.
13. Lee D, Lee D, Yun S, Lee C. Magnesium sulphate attenuates arterial pressure increase during laparoscopic cholecystectomy. Br J Anaesth 2009; 103(4): 484-9.
14. Gold M, Sachs D, Grossnoff D, Hurrington G, Skillman C. Use of esmolol during anaesthesia to treat tachycardia and hypertension. Anesth Analg1989; 68: 101-104.
15. Koivusalo AM, Schenin M, Tikkanen I, Yli-Suomu T, Ristkari S, Laakso J, et al. Effect of esmolol to haemodynamic response to CO2 pneumoperitoneum for laparoscopic surgery. Acta Anaesthesiol Scand 1998; 42: 510-517.
16. Magnusson J, Warner O, Carlsson C, Norden N, Pettersson K.I. Metaprolol, fentanyl and stress response to microlyangoscopy- effect on arterial pressure, heart rate and plasma concentration of catecholamines, ACTH and cortisol. Br J Anaesth 1983; 55(5): 405-414.
17. Diamant M, Benumot JL, Saidman IJ. Haemodynamics of increased intra-abdominal pressure interaction with hypovolaemia and halothane anaesthesia. Anaesthesiology 1978; 48: 23-27.
18. Ishizaki Y, Bandae Y, Shimomura K, Abe H, Ohtomo Y, Idezuki Y. Safe intra-abdominal pressure of CO2 pneumoperitoneum during laparoscopic surgery. Surgery 1993; 114: 549-54.
### Table 1

Patient’s characteristics and duration of surgery (Mean ± SD)

|                  | Group M (n=25) | Group S (n=25) | P Value |
|------------------|----------------|----------------|---------|
| Age (Years)      | 30.4±5.12      | 31.4±5.36      | 0.45    |
| Sex (M/F)        | 9/21           | 11/19          |         |
| Weight (kg)      | 45.24±8.16     | 47.88±9.4      | 0.51    |
| Duration of surgery (min) | 45.4±6.24    | 44.36±5.26     | 0.54    |

### Table 2

Changes in Mean Arterial Pressure (Mean ± SD)

|                  | Group M          | Group S          | Statistical Significance |
|------------------|------------------|------------------|--------------------------|
| Preoperative     | 88.4±8.6         | 89.32±6.8        | P>0.05; NS               |
| After intubation | 100.4±10.6       | 102.4±11.2       | P>0.05; NS               |
| Before pneumo-PP | 97.6±10.8        | 98.6±11.24       | P>0.05; NS               |
| Peritoneum (PP)  |                  |                  |                          |
| 15 min after PP  | 95.4±10.4        | 109±12.7         | P<0.05; S                |
| 30 min after PP  | 96.6±11.6        | 108±12.6         | P<0.05; S                |
| After release of PP | 90.4±9.2         | 101.8±11.4       | P<0.05; S                |
| After extubation | 94.8±10.36       | 104.6±10.6       | P<0.05; S                |

S –Significant, NS –Not Significant

### Table 3

Changes in Heart Rate (Mean ± SD)

|                  | Group M          | Group S          | Statistical Significance |
|------------------|------------------|------------------|--------------------------|
| Preoperative     | 80.2±6.3         | 81.34±4.6        | P>0.05; NS               |
| After intubation | 97.6±10.44       | 100.2±11.6       | P<0.05; NS               |
| Before pneumo-PP | 86.6±9.4         | 88.4±8.8         | P>0.05; NS               |
| Peritoneum (PP)  |                  |                  |                          |
| 15 min after PP  | 78.2±8.8         | 93.4±11.4        | P<0.05; S                |
| 30 min after PP  | 80.4±10.4        | 94.8±11.6        | P<0.05; S                |
| After release of PP | 79.4±9.6         | 90.2±10.4        | P<0.05; S                |
| After extubation | 85.2±10.4        | 98.8±11.6        | P<0.05; S                |

S –Significant, NS –Not Significant
Table 4
Distribution of patients according to adverse effects. Values are in number

| Adverse effects | Group M | Group S | Statistical Significance |
|-----------------|---------|---------|--------------------------|
| Bradycardia     | 0       | 0       | -                        |
| Hypotension     | 0       | 0       | -                        |
| Hypertension    | 0       | 13      | P< 0.05, S               |

S = Significant, NS = Not significant

AUTHORS:
1. Dhurjoti Prosad Bhattacharjee
2. Sujata Ghosh
3. Souvik Saha
4. Debadas Saha
5. Gautam Piplai
6. Parveen Banu
7. Kabita Dubey
8. Shibshankar Roy Chowdhury

PARTICULARS OF CONTRIBUTORS:
1. Professor, Department of Anaesthesiology, Calcutta National Medical College.
2. Assistant Professor, Department of Anaesthesiology, Calcutta National Medical College.
3. RMO cum Clinical Tutor, Department of Anaesthesiology, Calcutta National Medical College.
4. Professor, Department of Anaesthesiology, Calcutta National Medical College.
5. Associate Professor, Department of Anaesthesiology, Calcutta National Medical College.
6. Assistant Professor, Department of Anaesthesiology, Calcutta National Medical College.
7. Ex MD PGT, Department of Anaesthesiology, Calcutta National Medical College.
8. Associate Professor, Department of General Surgery, Calcutta National Medical College.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Dhurjoti Prosad Bhattacharjee,
Res: 38/11A, Mondal Para Lane,
Kolkata -700090.
E-mail: dhurjotib@yahoo.com

Date of Submission: 12/07/2015.
Date of Peer Review: 13/07/2015.
Date of Acceptance: 27/07/2015.
Date of Publishing: 31/07/2015.

FINANCIAL OR OTHER COMPETING INTERESTS: None